New Delhi, Oct. 6 -- A newly listed stock has seen a solid gain of over 80% in less than two months, and despite this sharp rise, domestic brokerage firm Motilal Oswal Financial Services has a "buy" recommendation on it, with a target price implying 20% upside potential.

We are discussing Molbio Diagnostics, a Goa-based healthcare company that develops fast, affordable, and accurate diagnostic tests. Its solutions help detect infectious and non-communicable diseases, making testing more accessible to people.

Molbio Diagnostics share price was listed on the Indian bourses on 17 August this year. At the current market price of Rs.1,475.50, it is up 83% from its IPO price of Rs.807 in less than two months.

Over the last month, the stock h...